Bioventus is reported to have delayed its US $150MM initial public offering.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.
Earlier this month, Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017. Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.
Bioventus is reported to have delayed its US $150MM initial public offering.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.
Earlier this month, Bioventus entered into an agreement with Seikagaku to continue U.S....
Bioventus is reported to have delayed its US $150MM initial public offering.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.
Earlier this month, Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUPARTZ FX™ viscosupplement through May 2019, following expiration of current terms in May 2017. Seikagaku and Bioventus had entered into an exclusive agreement for U.S. distribution of SUPARTZ® injectable treatment for knee OA pain in 1Q12.
Copy to clipboard 
